Literature DB >> 15763191

Chemotherapy for retinoblastoma.

Helen S L Chan1, Brenda L Gallie, Francis L Munier, Maja Beck Popovic.   

Abstract

Retinoblastoma is the most common eye cancer in children. Pilot studies of chemotherapy for intraocular retinoblastoma have been reported by several groups, using different combinations, dosages, schedules, and durations of carboplatin, etoposide, or teniposide, with or without vincristine, and with or without cyclosporine to counteract multidrug resistance. All studies of chemotherapy for intraocular retinoblastoma have included consolidation by focal therapy, with or without radiation. Chemotherapy alone reduces tumor size but does not cure retinoblastoma. Focal therapy, consisting of photocoagulation, thermotherapy, cryotherapy, or brachytherapy, is necessary to consolidate chemotherapy response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763191     DOI: 10.1016/j.ohc.2004.11.002

Source DB:  PubMed          Journal:  Ophthalmol Clin North Am        ISSN: 0896-1549


  32 in total

1.  Differential expression of folate receptor-alpha, sodium-dependent multivitamin transporter, and amino acid transporter (B (0, +)) in human retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cell lines.

Authors:  Jwala Jwala; Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Sai Hanuman Sagar Boddu; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-02-03       Impact factor: 2.671

2.  Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma.

Authors:  Rachel C Brennan; Ibrahim Qaddoumi; Catherine A Billups; Tammy L Free; Barrett G Haik; Carlos Rodriguez-Galindo; Matthew W Wilson
Journal:  Br J Ophthalmol       Date:  2015-04-14       Impact factor: 4.638

3.  Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro.

Authors:  Nahyoung G Lee; Jesse L Berry; Tom C Lee; Annie T Wang; Scott Honowitz; A Linn Murphree; Neeta Varshney; David R Hinton; Amani A Fawzi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

4.  Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.

Authors:  Jena J Steinle; Qiuhua Zhang; Karin Emmons Thompson; Jordan Toutounchian; C Ryan Yates; Carl Soderland; Fan Wang; Clinton F Stewart; Barrett G Haik; J Scott Williams; J Scott Jackson; Timothy D Mandrell; Dianna Johnson; Matthew W Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-30       Impact factor: 4.799

Review 5.  Retinoblastoma: an overview.

Authors:  Anish Ray; Dan S Gombos; Tribhawan S Vats
Journal:  Indian J Pediatr       Date:  2012-03-16       Impact factor: 1.967

6.  Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Christina Decatur; Timothy G Murray; Samuel K Houston; Milena Lopez-Cavalcante; Eleut Hernandez; Magda Celdran; Nikesh Shah; William Feuer; Theodore Lampidis
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-27       Impact factor: 4.799

7.  Epidemiological trends in 1452 cases of retinoblastoma from the Surveillance, Epidemiology, and End Results (SEER) registry.

Authors:  Michael T Andreoli; Felix Y Chau; Michael J Shapiro; Yannek I Leiderman
Journal:  Can J Ophthalmol       Date:  2017-07-22       Impact factor: 1.882

8.  Identification of the distance between the homologous halves of P-glycoprotein that triggers the high/low ATPase activity switch.

Authors:  Tip W Loo; David M Clarke
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

9.  Expression of heat shock protein 27 and alpha-crystallins in human retinoblastoma after chemoreduction.

Authors:  S Kase; J G Parikh; N A Rao
Journal:  Br J Ophthalmol       Date:  2008-09-23       Impact factor: 4.638

10.  In vivo growth of retinoblastoma in a newborn infant.

Authors:  Parag K Shah; V Narendran; N Kalpana
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.